Condition

Pancreatic Cancer

Find a Doctor

Brian M. Wolpin

Dana-Farber Cancer Institute, Inc.
Oncology, Internal Medicine
Male
Practicing approx. 20 years

Bio


Brian Wolpin is an Oncologist and an Internal Medicine specialist in Boston, Massachusetts. Dr. Wolpin is a global expert in Pancreatic Cancer. He has been an author on 177 peer reviewed articles and participated in 6 clinical trials in the past 15 years. In particular, he has been an author on 113 peer reviewed articles and participated in 6 clinical trials regarding Pancreatic Cancer. He is licensed to treat patients in MA.

Contact

450 Brookline Ave
Boston, MA 02215, US

Latest Advances


Latest Advance
Study
  • Condition: Advanced or Metastatic Colorectal Cancer
  • Journal: JAMA
  • Treatment Used: High-Dose vs Standard-Dose Vitamin D3 Supplementation
  • Number of Patients: 139
  • Published —
The study determined if high-dose vitamin D3 added to standard chemotherapy improves outcomes in patients with metastasis from colorectal cancer. They evaluated this by providing every two weeks a higher dose of vitamin D3 to a group compared to the standard dosage.

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Radiation
  • Participants: 25
  • Start Date: July 23, 2020
A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 52
  • Start Date: May 27, 2020
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Radiation
  • Participants: 30
  • Start Date: May 18, 2020
Nivolumab and Ipilimumab and Radiation Therapy in Metastatic, Microsatellite Stable Pancreatic Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 825
  • Start Date: January 31, 2020
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug, Radiation, Procedure
  • Participants: 160
  • Start Date: August 10, 2018
A Randomized Phase 2 Study of Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Contact

450 Brookline Ave
Boston, MA 02215, US

Affiliations

  • Dana-Farber Cancer Institute
  • Brigham And Women's Hospital

Credentials

  • Graduate InstitutionHarvard Medical School
    2001
  • Licenses
    Internal Medicine in MA
  • Board Certifications
    Medical Oncology

Insurance

Contact them to find out if they accept your insurance plan.